Table 4. Correlation of immune-cell markers density with overall (OS) and progression-free (PFS) survival (Mentel-Cox analysis).
OS (months) | P | PFS (months) | P | |
---|---|---|---|---|
CD3 | ||||
low | 36 | 0.02 | 25 | 0.04 |
high | 62 | 48 | ||
CD8 | ||||
low | 35 | 0.01 | 24 | 0.01 |
high | 48 | 48 | ||
CD57 | ||||
low | 26 | 0.02 | 25 | 0.04 |
high | 48 | 48 | ||
Granzyme b | ||||
low | 48 | 0.3 | 35 | 0.3 |
high | 44 | 44 | ||
CD4 | ||||
low | 48 | 0.6 | 35 | 0.4 |
high | 44 | 35 | ||
CD20 | ||||
low | 44 | 0.3 | 36 | 0.3 |
high | 48 | 36 | ||
CD163 | ||||
low | 44 | 0.4 | 35 | 0.2 |
high | 35 | 35 | ||
S100 | ||||
low | 44 | 0.4 | 24 | 0.1 |
high | 48 | 42 | ||
PDL1 | ||||
low | 35 | 0.4 | 36 | 0.6 |
high | 60 | 36 | ||
CTLA4-lymphocytes | ||||
negative | 44 | 0.4 | 35 | 0.4 |
positive | 44 | 35 | ||
CTLA4-tumor cells | ||||
low | 48 | 0.05 | 42 | 0.05 |
high | 32 | 19 |